Mitchell L Drumm

US Patent:

6730777, May 4, 2004

Filed:

Jun 6, 1995

Appl. No.:

08/469630

Inventors:

Lap-Chee Tsui - Toronto, CA
John R. Riordan - Toronto, CA
Francis S. Collins - Ann Arbor MI
Johanna M. Rommens - Willowdale, CA
Michael C. Iannuzzi - Ann Arbor MI
Bat-Sheva Kerem - Toronto, CA
Mitchell L. Drumm - Ann Arbor MI
Manuel Buchwald - Toronto, CA

Assignee:

HSC Research Development Corporation - Toronto
University of Michigan - Ann Arbor MI

International Classification:

C07K 1400

US Classification:

530350

Abstract:

The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

US Patent:

6902907, Jun 7, 2005

Filed:

Jun 2, 1994

Appl. No.:

08/252778

Inventors:

Lap-Chee Tsui - Toronto, CA
John R. Riordan - Toronto, CA
Francis S. Collins - Ann Arbor MI, US
Johanna M. Rommens - Willowdale, CA
Michael C. Iannuzzi - Ann Arbor MI, US
Bat-Sheva Kerem - Toronto, CA
Mitchell L. Drumm - Ann Arbor MI, US
Manuel Buchwald - Toronto, CA

Assignee:

HSC Research Development Corporation - Toronto
The Board of Regents Acting for and on Behalf of The University of Michigan - Ann Arbor MI

International Classification:

C12P021/06
C07K014/00

US Classification:

435 691, 4352523, 4353201, 435325, 536 231, 530350

Abstract:

The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

US Patent:

6984487, Jan 10, 2006

Filed:

Sep 20, 1993

Appl. No.:

08/123864

Inventors:

Lap-Chee Tsui - Toronto, CA
John R. Riordan - Toronto, CA
Francis S. Collins - Ann Arbor MI, US
Johanna M. Rommens - Willowdale, CA
Michael C. Iannuzzi - Ann Arbor MI, US
Bat-Sheva Kerem - Toronto, CA
Mitchell L. Drumm - Ann Arbor MI, US
Manuel Buchwald - Toronto, CA

Assignee:

HSC Research Development Corporation - Toronto
The Board of Regents Acting For and on Behalf of The University of Michigan - Ann Arbor MI

International Classification:

C12Q 1/68
C07K 14/00
C07H 21/04

US Classification:

435 6, 536 231, 530350

Abstract:

The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

US Patent:

20090162855, Jun 25, 2009

Filed:

Nov 3, 2008

Appl. No.:

12/264165

Inventors:

Mitchell Drumm - Brecksville OH, US
Rebecca Darrah - Strongsville OH, US
Paul Smith - Mayfield Village OH, US
Steven Martin - Shawnee KS, US
Michael Knowles - Chapel Hill NC, US
Steven Strausbaugh - Novelty OH, US
Robert Schilz - Shaker Heights OH, US

Assignee:

CASE WESTERN RESERVE UNIVERSITY - Cleveland OH

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

A method of determining a genetic component contributing to the severity of a pulmonary disease in a patient comprises determining the presence or absence of one or more single nucleotide polymorphisms (SNPs) in the Endothelin Receptor A (EDNRA) gene or the Interleukin-8 (IL-8) gene of the patient. The SNPs are rs5335 or rs1801708 for EDNRA, or rs4O73 for IL-8. The pulmonary disease may be cystic fibrosis or lymphangioleimyomatosis. Determining the presence or absence of one or more of SNPs rs5335 or rs1801708 in the EDNRA gene or rs4073 in the IL-8 gene of the patient may also be used in a method of treating a patient having a pulmonary disease. A kit may comprise one or more probes for determining the presence or absence of one or more of SNPs rs5335 and rs1801708 in the EDNRA gene or the SNP rs4073 in the IL-8 gene.

US Patent:

20130274132, Oct 17, 2013

Filed:

Sep 30, 2011

Appl. No.:

13/876712

Inventors:

Lisa Strug - Toronto, CA
Lei Sun - Toronto, CA
Johanna M. Rommens - Toronto, CA
Garry Cutting - Towson MD, US
Michael Knowles - Chapel Hill NC, US
Mitchell L. Drumm - Brecksville OH, US
Peter Durie - Toronto, CA

Assignee:

Hospital for Sick Children - Toronto ON
Case Western Reserve University - Cleveland OH
Univeristy of North Carolina at Chapet Hill - Chapel Hill NC
The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

506 9, 435 611

Abstract:

Disclosed herein are compositions and methods for and treating Cystic Fibrosis lung disease severity and/or secondary manifestations, including meconium ileus and CF related liver disease.

US Patent:

54340861, Jul 18, 1995

Filed:

Dec 9, 1993

Appl. No.:

8/164636

Inventors:

Francis S. Collins - Ann Arbor MI
Mitchell L. Drumm - Ann Arbor MI
David C. Dawson - Ann Arbor MI
Daniel J. Wilkinson - Ypsilanti MI

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

G01N 3300

US Classification:

436125

Abstract:

Cystic fibrosis (CF), a lethal genetic disease associated with a defect in Cl transport, is caused by mutations in the gene coding for cystic fibrosis transmembrane conductance regulator (CFTR). Surprisingly, not only wild type CFTR, but several naturally-occurring CFTR mutants carrying a defect in the first nucleotide binding fold (NFB1) all expressed cAMP-activatable Cl currents. Treatment of the CFTR mutants with appropriate concentrations of methylxanthine phosphodiesterase inhibitor (which increases cAMP levels) activated Cl conductance to near wild type levels. The present invention thus provides a new avenue for treating cystic fibrosis by the administration of therapeutically effective amounts of compounds which elevate cAMP levels. Dosage and patient responsiveness to treatment, as well as relative efficacies of the compounds being or to be administered can also be determined in accordance with the methods of present invention.

US Patent:

62011073, Mar 13, 2001

Filed:

Jun 6, 1995

Appl. No.:

8/469617

Inventors:

Tsui Lap-Chee - Toronto, CA
John R. Riordan - Toronto, CA
Francis S. Collins - Ann Arbor MI
Johanna M. Rommens - Willowdale, CA
Michael C. Iannuzzi - Ann Arbor MI
Bat-Sheva Kerem - Toronto, CA
Mitchell L. Drumm - Ann Arbor MI
Manuel Buchwald - Toronto, CA

Assignee:

HSC Research Development Corporation - Toronto
The Board of Regents, Acting for and on Behalf of the University of
Michigan - Ann Arbor MI

International Classification:

C07K 1600
A61K 39395

US Classification:

5303871

Abstract:

The cystic fibrosis gene and its gene product are described for both the normal and mutant forms. The genetic and protein information is used in developing DNA diagnosis, protein diagnosis, carrier and patient screening, drug and gene therapy, cloning of the gene and manufacture of the protein, and development of cystic fibrosis affected animals.

US Patent:

56021100, Feb 11, 1997

Filed:

Jan 26, 1995

Appl. No.:

8/378638

Inventors:

Mitchell L. Drumm - Brecksville OH
Thomas J. Kelley - Mayfield Heights OH

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 3170
A61K 3152
A61K 31445
A61K 3144

US Classification:

514 47

Abstract:

A method and composition for treating cystic fibrosis comprising administering to a patient a first component, a second component, and preferably a third component. The first component is an inhibitor which is specific for a cGMP-inhibited type III cAMP phosphodiesterase, preferably milrinone or amrinone; the second component is an adenylate cyclase activator, preferably forskolin, isoproterenol or albuterol; the third component is cAMP or a cAMP analog which activates protein kinase A.